
Two recently approved treatments offer newfound hope for patients in the early stages of Alzheimer’s disease, but most people who could benefit will likely be deemed ineligible, a new study finds. Alzheimer’s affects about 6.7 million Americans age 65 and older. But only about 8% to 17% of older adults with early signs of the… read on > read on >